CR20120570A - Heterociclilbencilpirazoles sustituidos y uso de los mismos - Google Patents

Heterociclilbencilpirazoles sustituidos y uso de los mismos

Info

Publication number
CR20120570A
CR20120570A CR20120570A CR20120570A CR20120570A CR 20120570 A CR20120570 A CR 20120570A CR 20120570 A CR20120570 A CR 20120570A CR 20120570 A CR20120570 A CR 20120570A CR 20120570 A CR20120570 A CR 20120570A
Authority
CR
Costa Rica
Prior art keywords
diseases
prevention
treatment
heterociclilbencilpirazoles
replaced
Prior art date
Application number
CR20120570A
Other languages
English (en)
Spanish (es)
Inventor
Michael Haerter
Hartmut Beck
Susanne Greschat
Peter Ellinghaus
Kerstin Berhoerster
Joachim Schuhmacher
Original Assignee
Bayer Ip Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=44063276&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CR20120570(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Bayer Ip Gmbh filed Critical Bayer Ip Gmbh
Publication of CR20120570A publication Critical patent/CR20120570A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4245—Oxadiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/06—Antiarrhythmics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Rheumatology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Vascular Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Ophthalmology & Optometry (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Immunology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pulmonology (AREA)
  • Dermatology (AREA)
  • Hospice & Palliative Care (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Obesity (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
CR20120570A 2010-05-08 2012-11-08 Heterociclilbencilpirazoles sustituidos y uso de los mismos CR20120570A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP10004855 2010-05-08

Publications (1)

Publication Number Publication Date
CR20120570A true CR20120570A (es) 2013-04-22

Family

ID=44063276

Family Applications (1)

Application Number Title Priority Date Filing Date
CR20120570A CR20120570A (es) 2010-05-08 2012-11-08 Heterociclilbencilpirazoles sustituidos y uso de los mismos

Country Status (26)

Country Link
US (2) US20130172311A1 (enExample)
EP (1) EP2569312B1 (enExample)
JP (1) JP5727002B2 (enExample)
KR (1) KR20130108997A (enExample)
CN (1) CN103003269B (enExample)
AR (1) AR081368A1 (enExample)
AU (1) AU2011252223A1 (enExample)
BR (1) BR112012028651A2 (enExample)
CA (1) CA2798375A1 (enExample)
CO (1) CO6640218A2 (enExample)
CR (1) CR20120570A (enExample)
CU (1) CU20120157A7 (enExample)
DO (1) DOP2012000284A (enExample)
EA (1) EA201291167A1 (enExample)
EC (1) ECSP12012288A (enExample)
ES (1) ES2462522T3 (enExample)
IL (1) IL222851A0 (enExample)
MA (1) MA34939B1 (enExample)
MX (1) MX2012012960A (enExample)
PE (1) PE20130228A1 (enExample)
PH (1) PH12012502202A1 (enExample)
SG (1) SG185459A1 (enExample)
TN (1) TN2012000531A1 (enExample)
TW (1) TW201200510A (enExample)
UY (1) UY33369A (enExample)
WO (1) WO2011141326A1 (enExample)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101688247A (zh) * 2007-05-01 2010-03-31 希尔氏宠物营养品公司 猫科动物骨关节炎的诊断方法和组合物
WO2008141731A2 (en) * 2007-05-18 2008-11-27 Bayer Healthcare Ag Inhibitors of hypoxia inducible factor (hif) useful for treating hyper-proliferative disorders and diseases associated with angiogenesis
EA201291167A1 (ru) * 2010-05-08 2013-05-30 Байер Интеллектуэль Проперти Гмбх Замещенные гетероциклилбензилпиразолы и их применение
UA114915C2 (uk) 2012-07-02 2017-08-28 Монсанто Текнолоджи Ллс Спосіб одержання 3,5-дизаміщених 1,2,4-оксадіазолів (варіанти)
WO2014031928A2 (en) * 2012-08-24 2014-02-27 Philip Jones Heterocyclic modulators of hif activity for treatment of disease
EP2888253A4 (en) 2012-08-24 2016-01-06 Univ Texas HETEROCYCLIC HIF ACTIVITY MODULATORS FOR THE TREATMENT OF DISEASES
DK2888255T3 (en) 2012-08-24 2018-10-29 Univ Texas HETOCYCLIC MODULATORS OF HIF ACTIVITY FOR TREATMENT OF DISEASE
WO2015130790A2 (en) 2014-02-25 2015-09-03 Board Of Regents, University Of Texas System Salts of heterocyclic modulators of hif activity for treatment of disease
US10191597B2 (en) 2015-06-30 2019-01-29 Synaptics Incorporated Modulating a reference voltage to preform capacitive sensing
WO2018131657A1 (ja) * 2017-01-13 2018-07-19 日産化学工業株式会社 芳香族ジアミン化合物前駆体の製造方法
WO2021216530A1 (en) 2020-04-20 2021-10-28 Akebia Therapeutics, Inc. Treatment of viral infections, of organ injury, and of related conditions using a hif prolyl hydroxylase inhibitor or a hif-alpha stabilizer
CN115944626B (zh) * 2022-12-08 2024-04-19 桂林医学院附属医院 小分子化合物在制备抗缺氧或缺血再灌注损伤药物中的应用
AU2024371427A1 (en) * 2023-10-30 2026-06-04 Pretzel Therapeutics, Inc. Compositions and inhibitors of polrmt

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6610726B2 (en) * 2001-06-29 2003-08-26 North Shore-Long Island Jewish Research Institute Compositions and agents for modulating cellular proliferation and angiogenesis
EP1613614A2 (en) 2003-04-03 2006-01-11 Merck & Co., Inc. Di-aryl substituted pyrazole modulators of metabotropic glutamate receptor-5
CN1842332A (zh) * 2003-06-30 2006-10-04 Hif生物公司 化合物、组合物及方法
JP4499721B2 (ja) 2003-06-30 2010-07-07 ヒフ バイオ，インク． 化合物、組成物および方法
GB0508472D0 (en) * 2005-04-26 2005-06-01 Glaxo Group Ltd Compounds
WO2007065010A2 (en) 2005-12-02 2007-06-07 Hif Bio, Inc. Anti-angiogenesis compounds
WO2008141731A2 (en) * 2007-05-18 2008-11-27 Bayer Healthcare Ag Inhibitors of hypoxia inducible factor (hif) useful for treating hyper-proliferative disorders and diseases associated with angiogenesis
CA2743424A1 (en) * 2008-11-14 2010-05-20 Michael Haerter Heteroaromatic compounds for use as hif inhibitors
DE102008057344A1 (de) * 2008-11-14 2010-05-20 Bayer Schering Pharma Aktiengesellschaft Aminoalkyl-substituierte Aryl-Verbindungen und ihre Verwendung
AU2009316019A1 (en) * 2008-11-14 2010-05-20 Bayer Intellectual Property Gmbh Heterocyclically substituted aryl compounds as HIF inhibitors
EP2202232A1 (en) 2008-12-26 2010-06-30 Laboratorios Almirall, S.A. 1,2,4-oxadiazole derivatives and their therapeutic use
ES2405054T3 (es) 2009-01-23 2013-05-30 Bristol-Myers Squibb Company Derivados de pirazol-1,2,4-oxadiazol como agonistas de esfingosina-1-fosfato
EA201291167A1 (ru) * 2010-05-08 2013-05-30 Байер Интеллектуэль Проперти Гмбх Замещенные гетероциклилбензилпиразолы и их применение

Also Published As

Publication number Publication date
CN103003269B (zh) 2015-11-25
WO2011141326A1 (de) 2011-11-17
KR20130108997A (ko) 2013-10-07
TW201200510A (en) 2012-01-01
EP2569312B1 (de) 2014-03-26
UY33369A (es) 2011-12-01
US20120028950A1 (en) 2012-02-02
EP2569312A1 (de) 2013-03-20
CN103003269A (zh) 2013-03-27
US8470811B2 (en) 2013-06-25
PE20130228A1 (es) 2013-03-15
US20130172311A1 (en) 2013-07-04
AU2011252223A1 (en) 2012-12-06
IL222851A0 (en) 2012-12-31
ECSP12012288A (es) 2012-12-28
CA2798375A1 (en) 2011-11-17
TN2012000531A1 (en) 2014-04-01
CU20120157A7 (es) 2013-03-27
JP5727002B2 (ja) 2015-06-03
EA201291167A1 (ru) 2013-05-30
JP2013526497A (ja) 2013-06-24
MA34939B1 (fr) 2014-03-01
MX2012012960A (es) 2012-12-17
DOP2012000284A (es) 2013-03-31
AR081368A1 (es) 2012-08-29
ES2462522T3 (es) 2014-05-23
BR112012028651A2 (pt) 2016-08-09
PH12012502202A1 (en) 2013-02-04
CO6640218A2 (es) 2013-03-22
SG185459A1 (en) 2012-12-28

Similar Documents

Publication Publication Date Title
LTC2137143I2 (lt) Pleuromutilino dariniai, skirti mikrobų sukeltų ligų gydymui
CU20120157A7 (es) Heterociclilbencilpirazoles sustituidos y uso de los mismos
UY31228A1 (es) Ariloxazoles sustituidos y su uso
ECSP12012125A (es) Ariltriazolonas ligadas a bisarilo y su uso
MX381313B (es) Derivados de benzimidazol como moduladores de ror-gamma
DOP2014000043A (es) Pirimidinas anilladas sustituidas y uso de las mismas
SV2011003901A (es) Compuestos de arilo con sustituyentes heterocíclicos como inhibidores de hif
ECSP15001882A (es) Ácidos 5-aminotetrahidroquinolin-2-carboxílicos novedosos y su uso
UY33883A (es) Novedosos derivados heterocíclicos
PE20151023A1 (es) Triazolopirazinas
CO6771409A2 (es) Acidos 1-bencilcicloalquilcarboxilicos sustituidos y su uso
GT200900230A (es) 4-aril-1,4-dihidro-1,6-naftiridinamidas sustituidas y uso
UY34657A (es) ?derivados macrocíclicos para el tratamiento de enfermedades?.
CR20110485A (es) 2-acetamido-5-aril-1,2,4-triazolonas sustituidas y su uso
EA201790785A1 (ru) Производные тетрагидроизохинолина
DK3045456T3 (da) Bicyklisk substituerede uraciler og anvendelse heraf
EA201590953A1 (ru) Пирролидиновые модуляторы gpr40
CR11684A (es) Dihidropirazolonas sustituidas de hif-propil-4- como inhibidores hidroxilasa
CR11600A (es) Derivados de indazol
CU20170158A7 (es) Derivados sustituidos de 1-arilnaftiridina-3-carboxamidas y su utilidad en el tratamiento o prevención de enfermedades cardiovasculares y renales
ECSP14002542A (es) Nuevos 2h–indazoles como antagonistas del receptor ep2
PE20150167A1 (es) (r)-nifuratel, su uso para el tratamiento de las infecciones y sintesis de (r) y (s)-nifuratel
GT201300125A (es) 1h-pirazol-5-olato sódico sustituido
WO2015138276A3 (en) Retinoic acid receptor-related orphan receptor modulators and uses thereof
UY30135A1 (es) Quinolonas sustituidas iii